Maravai LifeSciences (MRVI) Stock Price, News & Analysis

Company Overview

Maravai LifeSciences, Inc. is a biotechnology company specializing in providing critical reagents, assays and services that support the development and manufacture of vaccines, gene therapies and other biologics. The company’s product portfolio spans nucleic acid labeling technologies, lipid nanoparticle components for mRNA delivery, high-purity plasmid DNA and protein analysis reagents. Through its cGMP-compliant manufacturing capabilities, Maravai enables clients ranging from academic researchers to leading biopharmaceutical firms to accelerate programs from early discovery through commercial scale production.

Founded through a series of strategic acquisitions, Maravai has integrated expertise from TriLink Biotechnologies, Cygnus Technologies, SurModics and Aldevron to build a unified platform for life-science innovation. These transactions have broadened the company’s offerings to include next-generation sequencing sample preparation, LNP formulation for mRNA vaccines, vsdetection systems for nucleic acids and proteins, and custom plasmid and protein manufacturing under stringent regulatory standards. This approach has allowed Maravai to maintain a diversified business model that addresses both research and commercial manufacturing needs.

Headquartered in San Diego, California, Maravai LifeSciences operates manufacturing and research facilities across North America, Europe and Asia. The company’s global footprint ensures timely supply chain support and regulatory alignment for biologics programs around the world. By upholding rigorous quality controls and leveraging a network of technical service teams, Maravai helps clients navigate complex regulatory requirements and optimize process development timelines.

Under the leadership of President and Chief Executive Officer Bradley Thompson, Maravai continues to invest in innovation and capacity expansion. The executive team combines deep experience in biologics, vaccine development and commercial operations, guiding the company’s mission to accelerate breakthroughs in public health and therapeutic research. Maravai’s integrated platform and commitment to quality position it as a key partner for organizations advancing next-generation medicines and vaccines.

Key Stats

• Today's Range: $2.63 to $2.77
• 50-Day Range: $1.96 to $2.89
• 52-Week Range: $1.67 to $10.03
• Volume: 912,371 shs
• Average Volume: 2.28 million shs
• Market Capitalization: $679.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.64
• Consensus Rating: Hold

Maravai LifeSciences Stock Analysis - MarketRank™

Maravai LifeSciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 282nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Maravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 4 buy ratings, 7 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Maravai LifeSciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.24) to ($0.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Maravai LifeSciences is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Maravai LifeSciences is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Maravai LifeSciences has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.29% of the float of Maravai LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Maravai LifeSciences has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Maravai LifeSciences has recently increased by 5.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Maravai LifeSciences does not currently pay a dividend.

Dividend Growth

Maravai LifeSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.23

Percentage of Shares Shorted

13.29% of the float of Maravai LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Maravai LifeSciences has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Maravai LifeSciences has recently increased by 5.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.64

News Sentiment

Maravai LifeSciences has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Maravai LifeSciences this week, compared to 11 articles on an average week.

Search Interest

3 people have searched for MRVI on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.11% of the stock of Maravai LifeSciences is held by insiders.

Percentage Held by Institutions

50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRVI Stock Analysis - Frequently Asked Questions

How have MRVI shares performed this year?

Maravai LifeSciences' stock was trading at $5.45 on January 1st, 2025. Since then, MRVI stock has decreased by 51.0% and is now trading at $2.67.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The firm's revenue for the quarter was down 26.9% on a year-over-year basis.
Read the conference call transcript.

When did Maravai LifeSciences IPO?

Maravai LifeSciences (MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Maravai LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRVI
• CIK: 1823239
• Web: www.maravai.com
• Phone: 858-546-0004
• Fax: N/A
• Employees: 610
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Maravai LifeSciences: $6.64
• High Price Target: $13.00
• Low Price Target: $2.00
• Potential Upside/Downside: +146.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$144.85 million
• Net Margins: -67.14%
• Pretax Margin: -120.56%
• Return on Equity: -12.91%
• Return on Assets: -6.87%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 5.96
• Quick Ratio: 5.17

Sales & Book Value

• Annual Sales: $259.18 million
• Price / Sales: 2.65
• Cash Flow: $0.61 per share
• Price / Cash Flow: 4.42
• Book Value: $2.28 per share
• Price / Book: 1.18

Miscellaneous

• Outstanding Shares: 254,660,000
• Free Float: 249,287,000
• Market Cap: $686.31 million
• Optionable: Optionable
• Beta: 0.28